New publications
Cyclin D1 expression may be a biomarker of penile cancer
Last reviewed: 02.07.2025
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
A new research paper titled "Cyclin D1 expression in penile cancer" was published in the journal Oncotarget.
In this new study, the researchers analyzed the expression profile of cyclin D1 in patients with penile cancer (PC) and identified possible correlations with clinical and histopathological features.
"However, there are few studies assessing the role of cyclin D1 in PCa, highlighting the need for initiatives aimed at understanding its actual role in the pathophysiology of this disease. Therefore, the present study aimed to characterize cyclin D1 expression in patients with PCa and determine possible correlations with clinical and histopathological features of the disease," the researchers wrote.
A study was performed on 100 patients diagnosed with PCa and treated in two reference hospitals in São Luís, Maranhão, Brazil, between 2013 and 2017. Clinical, epidemiological and histopathological data were reviewed, human papillomavirus (HPV) DNA was detected by polymerase chain reaction (PCR) and cyclin D1 expression was analyzed using immunohistochemistry.
Cyclin D1 protein expression in immunohistochemical analysis of histological sections. Source: Oncotarget (2024). DOI: 10.18632/oncotarget.28584
The data showed that the absence of cyclin D1 expression was significantly associated with HPV-positive histological subtypes (p = 0.001), while its expression was associated with high-grade tumors (p = 0.014), histological subtype (p = 0.001), the presence of sarcomatoid transformation (p = 0.04), and perineural invasion (p = 0.023). Patients with cyclin D1 expression had a lower disease-free survival compared with the cyclin D1-negative group, although the difference was not statistically significant.
"The results suggest that cyclin D1 may be a potential biomarker for PCa, particularly for worse prognosis," the researchers conclude.